ArcticZymes Technologies ASA (DE:B4V) has released an update.
ArcticZymes Technologies ASA has published a whitepaper highlighting their salt-active nuclease solutions, M-SAN HQ and SAN HQ GMP, which improve efficiency and reduce costs in viral vector manufacturing. The paper, demonstrating the enzymes’ ability to streamline downstream processing and produce cleaner viral vector products, positions ArcticZymes as a leader in the bioprocessing industry. CEO Michael B. Akoh emphasizes the company’s innovative approach to meet the complex needs of the sector with their specialized enzyme technologies.
For further insights into DE:B4V stock, check out TipRanks’ Stock Analysis page.
